Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
Open Access
- 27 March 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 13 (1), 158
- https://doi.org/10.1186/1471-2407-13-158
Abstract
Systemic inflammation has been linked with cancer development, cancer cachexia and poor outcome. Advanced lung cancer inflammation index (ALI) was developed to assess degree of systemic inflammation at the time of diagnosis in metastatic non-small cell lung (NSCLC) cancer patients.Keywords
This publication has 17 references indexed in Scilit:
- Primary Sjögren’s syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopeniaRheumatology International, 2012
- Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancerBritish Journal of Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- C-Reactive Protein and Risk of Lung CancerJournal of Clinical Oncology, 2010
- Neutrophil/lymphocyte ratio and its association with survival after complete resection in non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Lung CancerThe New England Journal of Medicine, 2008
- Cancer-related inflammationNature, 2008
- Inflammation and cancer: An ancient link with novel potentialsInternational Journal of Cancer, 2007
- Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care.2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2006